Accelerate Your business
growth with tailored
biotech intelligence
Unlock Opportunities, Forge Partnerships, and Make
Informed Decisions with Our Comprehensive Solutions
Some of our clients
Unique data sourcing process
leading to an exclusive data set
Over 1,000,000 regularly
updated clinical trials
65,000 companies with over
360,000 management contact details
Over 43,000 Biotech, Pharma and Medtech
assets available for licensing
Investor Database including
direct contact details
License agreements with payment
structures and original contract
BIOTECHGATE DIGITAL PARTNERING
Virtual business development & licensing event
Join five days of digital partnering, workshops and networking sessions. Establish new global connections thanks to pre-arranged one-on-one Zoom meetings.
Solutions by industry
Biotechgate is a versatile information source
catering to the entire life science industry.
What our clients say
“Since I started to use Biotechgate my prospective activities have become far less time-consuming and the collected information much more up-to-date which is most satisfactory.”
Business Development Manager at GreenLight Clinical
We have used Biotechgate for a year now and we have been very satisfied with the system so far. It has provided us with an enormous amount of business intelligence of our marketplace.
Managing Partner at Sourcia
Liftstream was compelled to subscribe to Biotechgate as it is really the only international database of the life sciences sector which is frequently updated by those who are listed on it. This ensures that you can access and retrieve information based on geography, therapy, modality, management or any other category of information which is important to your search.
CEO at Liftstream
Latest industry news
Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update
19 Jun 2025
Read moreElton John AIDS Foundation launches pilot schemes to accelerate access to Pre-Exposure Prophylaxis (PrEP) and reduce new HIV transmissions in England
19 Jun 2025
Read moreSimcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refractory Multiple Myeloma
19 Jun 2025
Read moreUpcoming Conferences